Monte Rosa Therapeutics, Inc. (GLUE) Operating income 2020–2025
Monte Rosa Therapeutics, Inc. (GLUE) annual operating income history from SEC filings — each fiscal year as reported.
-$54.2MFY2025 · since FY2020: -$28.0M → -$54.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$54.2M | +33.2% |
| FY2024 | -$81.1M | +43.4% |
| FY2023 | -$143.3M | -27.5% |
| FY2022 | -$112.4M | -54.2% |
| FY2021 | -$72.9M | -160.2% |
| FY2020 | -$28.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net incomeGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating marginGLUE Operating cash flowGLUE Free cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →